Will we ever have better glucocorticoids?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Immunology

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clim.2017.07.023PMID 28757452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis

  2017cited by this paper
• “Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements

  2017cited by this paper
• Glucocorticoids in rheumatoid arthritis: the picture is shaping up

  2017cited by this paper
• Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis

  2016cited by this paper
• Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

  2016cited by this paper
• Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort

  2016cited by this paper
• Novel glucocorticoids: where are we now and where do we want to go?

  2015cited by this paper
• Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects.

  2014cited by this paper
• EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

  2013cited by this paper
• Optimized glucocorticoid therapy: teaching old drugs new tricks.

  2013cited by this paper
• New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation.

  2013cited by this paper
• Liposomal drug formulations in the treatment of rheumatoid arthritis.

  2011cited by this paper
• The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation.

  2011cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

  2010cited by this paper
• Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice

  2010cited by this paper
• Genomic and nongenomic effects of glucocorticoids

  2008cited by this paper
• Optimised glucocorticoid therapy: the sharpening of an old spear.

  2005cited by this paper
• Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis

  2004cited by this paper
• Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes.

  2003cited by this paper

• Dexamethasone Inhibits White Adipose Tissue Browning

  2024cites this paper
• Nanomotors as Therapeutic Agents: Advancing Treatment Strategies for Inflammation‐Related Diseases

  2024cites this paper
• Glucocorticoids treatment and adverse infectious events in rheumatic diseases

  2024cites this paper
• Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts

  2024cites this paper
• Effect of a Herbal Formulation on Infection Prevention and Immune Regulation in Children with Frequent Relapse Nephrotic Syndrome

  2023cites this paper
• Identification of FDA‐approved drugs that increase mevalonate kinase in hyper IgD syndrome

  2023cites this paper
• Biased regulation of glucocorticoid receptors signaling.

  2023cites this paper
• Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats.

  2023cites this paper
• A plant‐derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy

  2022cites this paper
• The Role of Conformational Dynamics and Allostery in the Control of Distinct Efficacies of Agonists to the Glucocorticoid Receptor

  2022cites this paper
• Point mutation I634A in the glucocorticoid receptor causes embryonic lethality by reduced ligand binding

  2022cites this paper
• Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis

  2021cites this paper
• New insights into the fascinating world of glucocorticoids: the dexamethasone-miR-342-Rictor axis in regulatory T cells

  2021cites this paper
• Glucocorticoids: surprising new findings on their mechanisms of actions

  2020cites this paper
• Views on glucocorticoid therapy in rheumatology: the age of convergence

  2020cites this paper
• Multi-Component One Pot assisted Synthesis, Anti-bacterial Capabilities and Scanning Electron Microscopy of Novel Corticosteroid Thiopyran.

  2020cites this paper
• GR Dimerization and the Impact of GR Dimerization on GR Protein Stability and Half-Life

  2019cites this paper
• Topical and Systemic Corticosteroids

  2019cites this paper
• Liposomal dexamethasone inhibits tumor growth in an advanced human‐mouse hybrid model of multiple myeloma

  2019cites this paper
• A General Introduction to Glucocorticoid Biology

  2019cites this paper
• Physiologic Steroid Tapering

  2019cites this paper
• Early Targeted Combination Treatment With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs and Long‐Term Outcomes in Rheumatoid Arthritis: Ten‐Year Follow‐Up Results of a Randomized Clinical Trial

  2019cites this paper
• Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.

  2018cites this paper
• A Quick and Painless Reminder: The Pharmacotherapy of Rheumatoid Arthritis in Primary Practice

  2018cites this paper
• Strategies and Compounds to Circumvent Glucocorticoid-Induced Side Effects

  2018cites this paper
• A screening assay for Selective Dimerizing Glucocorticoid Receptor Agonists and Modulators (SEDIGRAM) that are effective against acute inflammation

  2018cites this paper
• Advances in targeted therapies 2017.

  2018cites this paper
• Therapeutic Mechanisms of Glucocorticoids.

  2018cites this paper
• Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review

  2017cites this paper